29th May 2015 12:50
FOR IMMEDIATE RELEASE 29 MAY 2015
ANNUAL GENERAL MEETING: 2015
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed. A summary of proxy votes is shown in the table below. Please also refer to the 'Notice of the 2015 Annual General Meeting' in the Report & Accounts - 31 December 2014 (page 55).
RESOLUTION | FOR + DISCRETION | % | AGAINST | % | WITHHELD |
1 | 37,051,623 | 91.52 | 3,432,424 | 8.48 | 300 |
2 | 40,327,447 | 99.61 | 156,900 | 0.39 | 0 |
3 | 40,327,447 | 99.61 | 156,900 | 0.39 | 0 |
4 | 40,443,946 | 99.90 | 40,000 | 0.10 | 0 |
5 | 40,441,085 | 99.90 | 41,800 | 0.10 | 1,462 |
6 (Special Resolution) | 40,323,858 | 99.61 | 159,762 | 0.39 | 727 |
For further information please see the Group's web site, www.immupharma.org, or contact:
END
For further information please contact:
ImmuPharma plc | + 44 (0) 20 7152 4080 |
Dimitri Dimitriou, Chief Executive Officer | |
Dr Robert Zimmer, President and Chief Scientific Officer | |
Lisa Baderoon, Head of Investor Relations
| + 44 (0) 7721 413496 |
Panmure, Gordon & Co., NOMAD & Broker | +44 (0) 20 7886 2500 |
Hugh Morgan Fred Walsh Duncan Monteith
|
Related Shares:
Immupharma